S Sridhar

“The Neksium acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the gastrointestinal (GI) therapy area.”

S Sridhar,
Managing Director,
Pfizer Ltd.

AstraZeneca AB, Sweden, has sold its antacid brand Neksium to Pfizer Ltd., which also owns Gelusil brand, for 75 crore. Neksium, with the active ingredient esomeprazole belongs to a class of pharmaceutical preparations called proton pump inhibitors (PPI), which are used effectively for reducing acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the acid peptic disorders (APD) spectrum.

With brands such as Gelusil and Mucaine, Pfizer Ltd. has been providing effective solutions in the antacid space for over 30 years. The company is uniquely well placed to grow the Neksium brand further through its existing reach, coverage, and equity in the GI therapy area


A New Cancer Treatment

10 Unbelievable Innovation in Medicine

 

Digital version